Funded by European Union’s Framework Programme for Research and Innovation “Horizon 2020”. Grant agreement ID: 874764.

Coronavirus related research led by REANIMA researchers: Prof. Christian Plank

Neurimmune AG and Ethris GmbH announced today an exclusive partnership to develop mRNA-encoded, neutralizing anti-SARS-CoV-2 antibodies administered by inhalation for the treatment of Covid-19. Companies expect to initiate clinical testing in 2020

The collaboration brings together Neurimmune’s expertise in developing human antibodies based on high-throughput immunoglobulin sequence analyses from Covid-19 patients who have recovered from the disease with Ethris’ proprietary and unique pulmonary SNIM®RNA therapeutics platform. Both companies will work together to rapidly develop an immunotherapy designed to produce therapeutic antibodies directly in the lungs of affected patients.